Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(33%)

Phase Distribution

Ph early_phase_1

33%

Ph phase_1

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Early Phase 1First-in-human

1(33.3%)

Phase 1Safety & dosage

2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 1

Trials by Phase

Early Phase 11 (33.3%)

Phase 12 (66.7%)

Trials by Status

completed267%

terminated133%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_1

Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis

NCT05487963

terminatedearly_phase_1

Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

NCT03159936

completedphase_1

Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study

NCT04468425

Clinical Trials (3)

Showing 3 of 3 trials

NCT05487963Phase 1

Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis

Completed

NCT03159936Early Phase 1

Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

Terminated

NCT04468425Phase 1

Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study

Completed

All 3 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 3